Scarica l'app Stockscreener
5.12
7.91%
-0.44
Dopo l'orario di chiusura:
5.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.56
Aprire:
$5.41
Volume 24 ore:
4.93M
Relative Volume:
2.77
Capitalizzazione di mercato:
$561.41M
Reddito:
-
Utile/perdita netta:
$-258.08M
Rapporto P/E:
-1.8618
EPS:
-2.75
Flusso di cassa netto:
$-202.32M
1 W Prestazione:
-32.54%
1M Prestazione:
-40.88%
6M Prestazione:
-68.80%
1 anno Prestazione:
-79.50%
Intervallo 1D:
$5.10
$5.435
Intervallo di 1 settimana:
$5.10
$7.275
Portata 52W:
$5.10
$26.98
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Nome
Rocket Pharmaceuticals Inc
Settore
Industria
Telefono
646-440-9100
Indirizzo
350 FIFTH AVENUE, NEW YORK, NY
Confronta RCKT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
5.12 | 561.41M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-30 | Iniziato | Wedbush | Outperform |
| 2024-12-18 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-01 | Iniziato | Morgan Stanley | Overweight |
| 2022-11-08 | Iniziato | Canaccord Genuity | Buy |
| 2022-11-01 | Iniziato | BTIG Research | Buy |
| 2022-07-08 | Iniziato | Raymond James | Outperform |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2021-02-18 | Iniziato | Needham | Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-12-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-07-02 | Iniziato | JP Morgan | Overweight |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2019-11-06 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-26 | Iniziato | Piper Jaffray | Overweight |
| 2019-04-23 | Iniziato | Robert W. Baird | Outperform |
| 2019-03-15 | Iniziato | BofA/Merrill | Buy |
| 2019-02-05 | Iniziato | Oppenheimer | Outperform |
| 2018-09-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-07-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Rocket Pharmaceuticals Inc Borsa (RCKT) Ultime notizie
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Thrivent Financial for Lutherans Sells 21,731 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? - MSN
Where are the Opportunities in (RCKT) - news.stocktradersdaily.com
Teacher Retirement System of Texas Raises Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 1-Year LowHere's Why - MarketBeat
Swiss National Bank Has $1.93 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals’ SWOT analysis: gene therapy stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals’ SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India
Cantor Fitzgerald maintains Overweight on Rocket Pharmaceuticals stock By Investing.com - Investing.com Canada
Charles Schwab Investment Management Inc. Has $8.25 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Cantor Fitzgerald maintains Overweight on Rocket Pharmaceuticals stock - Investing.com India
(RCKT) Technical Pivots with Risk Controls - news.stocktradersdaily.com
PNC Financial Services Group Inc. Increases Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Bank of New York Mellon Corp Buys 9,949 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Fanconi Anemia Pipeline 2025: FDA Approvals and Clinical Trials - openPR.com
What technical indicators reveal about RCKT stock - US Post News
Steward Partners Investment Advisory LLC Has $84,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by Arizona State Retirement System - Defense World
BMO Capital Markets Begins Coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
(RCKT) Investment Analysis and Advice - news.stocktradersdaily.com
BMO Capital Initiates Coverage on Rocket Pharmaceuticals With Outperform Rating, $50 Price Target - Marketscreener.com
BMO Capital Initiates Coverage of Rocket Pharmaceuticals (RCKT) with Outperform Recommendation - Nasdaq
Rocket Pharmaceuticals: A Buy Rating for Its Pioneering Gene Therapy Approach and Promising Pipeline - TipRanks
BMO Capital sets $50 target for Rocket Pharmaceuticals stock - Investing.com India
BMO Capital sets $50 target for Rocket Pharmaceuticals stock By Investing.com - Investing.com Canada
Private Advisor Group LLC Acquires Shares of 13,199 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by New York State Common Retirement Fund - Defense World
Rhumbline Advisers Has $1.25 Million Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Research Analysts Set Expectations for RCKT FY2025 Earnings - Defense World
Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory - Insider Monkey
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Handelsbanken Fonder AB Has $290,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $15.00 by Analysts at The Goldman Sachs Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Raised to $52.00 at Scotiabank - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $36.00 at Canaccord Genuity Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 1-Year Low on Analyst Downgrade - Defense World
Rocket Pharmaceuticals Inc (NASDAQ: RCKT)’s Stock Adds 0.53%, Making It A Good Investment - Stocks Register
Scotiabank raises Rocket Pharmaceuticals target to $52 - Investing.com
What is William Blair’s Estimate for RCKT Q1 Earnings? - Defense World
What is Leerink Partnrs’ Estimate for RCKT Q2 Earnings? - Defense World
Chardan Capital Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $54.00 - Defense World
Needham & Company LLC Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $42.00 - Defense World
Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs - MSN
When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit? - Yahoo Finance Australia
Decoding Rocket Pharmaceuticals Inc (RCKT): A Strategic SWOT Ins - GuruFocus
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus - MSN
Rocket Pharmaceuticals Advances Gene Therapy Pipeline - TipRanks
Rocket Pharmaceuticals (NASDAQ:RCKT) Posts Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 12-Month LowHere's What Happened - MarketBeat
Rocket Pharmaceuticals Inc Azioni (RCKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rocket Pharmaceuticals Inc Azioni (RCKT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schwartz Jonathan David | See Remarks |
May 17 '24 |
Sale |
23.35 |
2,754 |
64,306 |
169,659 |
| Schwartz Jonathan David | See Remarks |
Aug 16 '24 |
Sale |
18.50 |
2,710 |
50,135 |
166,949 |
| Schwartz Jonathan David | See Remarks |
Nov 21 '24 |
Sale |
13.05 |
3,097 |
40,416 |
163,852 |
| Patel Kinnari | See Remarks |
Feb 21 '25 |
Sale |
10.58 |
6,078 |
64,305 |
444,103 |
| Wilson Martin | General Counsel |
Feb 21 '25 |
Sale |
10.58 |
3,222 |
34,089 |
150,696 |
| Militello John | See Remarks |
Feb 21 '25 |
Sale |
10.58 |
2,737 |
28,957 |
65,757 |
| Shah Gaurav | CEO |
Feb 21 '25 |
Sale |
10.58 |
16,303 |
172,486 |
772,680 |
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):